{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:47:47Z","timestamp":1789591667805,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020584","name":"Region Hovedstadens Psykiatri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopsych.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:39:22Z","timestamp":1784702362000},"page":"875-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-470X","authenticated-orcid":false,"given":"Mette Kruse","family":"Klausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7143-1236","authenticated-orcid":false,"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.07.010_bib1","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/S0140-6736(25)01496-5","article-title":"Alcohol use disorders","volume":"406","author":"Rehm","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib4","first-page":"858","article-title":"The treatment gap in mental health care","volume":"82","author":"Kohn","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.biopsych.2026.07.010_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.biopsych.2026.07.010_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2026.07.010_bib7","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2026.07.010_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.biopsych.2026.07.010_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopsych.2026.07.010_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: Pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biopsych.2026.07.010_bib13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/phar.1639","article-title":"Liraglutide: A new option for the treatment of obesity","volume":"35","author":"Nuffer","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopsych.2026.07.010_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2026.07.010_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.107520","article-title":"Oral semaglutide in type 2 diabetes","volume":"34","author":"Anderson","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.biopsych.2026.07.010_bib16","author":"Kalra"},{"key":"10.1016\/j.biopsych.2026.07.010_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2026.07.010_bib18","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/dom.16152","article-title":"Glucagon-like peptide-1 analogues reduce alcohol intake","volume":"27","author":"O\u2019Farrell","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib20","first-page":"5","article-title":"Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.biopsych.2026.07.010_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: Insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"key":"10.1016\/j.biopsych.2026.07.010_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib23","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2026.07.010_bib24","article-title":"Glucagon-like Peptide-1 receptor agonists and alcohol use: A real-word observational study in a large, integrated health care system","volume":"6","author":"Palzes","year":"2025","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"10.1016\/j.biopsych.2026.07.010_bib25","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Investig"},{"key":"10.1016\/j.biopsych.2026.07.010_bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.07.010_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/apt.70596","article-title":"Real-world alcohol use disorder outcomes in patients with concurrent metabolic dysfunction: GLP-1 receptor agonists versus FDA-Approved AUD medications","volume":"63","author":"Gougol","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.07.010_bib29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.07.010_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.14309\/ajg.0000000000003585","article-title":"Association of glucagon-like Peptide-1 receptor agonists with liver-related outcomes and all-cause mortality in patients with harmful alcohol use: A target trial emulation study","volume":"121","author":"John","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: Cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2026.07.010_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopsych.2026.07.010_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopsych.2026.07.010_bib34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1037\/amp0000059","article-title":"Liking, wanting, and the incentive-sensitization theory of addiction","volume":"71","author":"Berridge","year":"2016","journal-title":"Am Psychol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1037\/h0058775","article-title":"Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain","volume":"47","author":"Olds","year":"1954","journal-title":"J Comp Physiol Psychol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105684","article-title":"An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents","volume":"115","author":"Edvardsson","year":"2025","journal-title":"EBiomedicine"},{"key":"10.1016\/j.biopsych.2026.07.010_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-025-00637-z","article-title":"The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: A systematic review and meta-analysis","volume":"21","author":"Sinha","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.biopsych.2026.07.010_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13098-025-02006-x","article-title":"Repurposing GLP-1 receptor agonists for alcohol use disorder: A systematic review and meta-analysis","volume":"18","author":"Nasrollahizadeh","year":"2026","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.biopsych.2026.07.010_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086454","article-title":"Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)","volume":"15","author":"Klausen","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopsych.2026.07.010_bib42","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib43","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamapsychiatry.2025.2508","article-title":"Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: A review","volume":"82","author":"Witkiewitz","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib45","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41380-025-03259-8","article-title":"Crosstalk between alcohol use disorder and obesity: Two sides of the same coin?","volume":"30","author":"Leggio","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/dom.70291","article-title":"Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use","volume":"28","author":"Vilsb\u00f8ll","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib47","series-title":"ECO 2025: Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases","author":"Novo Nordisk","year":"2025"},{"key":"10.1016\/j.biopsych.2026.07.010_bib48","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/add.15147","article-title":"Alcohol use disorder and the gut","volume":"116","author":"Haber","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.07.010_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-025-04494-3","article-title":"Exploring the rates of gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials","volume":"91","author":"Joy","year":"2026","journal-title":"Endocrine"},{"issue":"10540","key":"10.1016\/j.biopsych.2026.07.010_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib52","first-page":"241","article-title":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: An integrated analysis of 4,328 patients","volume":"8","author":"MacConell","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.biopsych.2026.07.010_bib53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115613","article-title":"Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease","volume":"213","author":"Mahalingam","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.biopsych.2026.07.010_bib56","article-title":"Semaglutide: FDA approves weight loss jab to treat severe liver disease","volume":"390","author":"Bowie","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2026.07.010_bib57","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/add.13757","article-title":"The relationship between different dimensions of alcohol use and the burden of disease-An update","volume":"112","author":"Rehm","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.07.010_bib58","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.ebiom.2015.11.023","article-title":"Alcohol consumption as a risk factor for acute and chronic pancreatitis: A systematic review and a series of meta-analyses","volume":"2","author":"Samokhvalov","year":"2015","journal-title":"EBiomedicine"},{"key":"10.1016\/j.biopsych.2026.07.010_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopsych.2026.07.010_bib60","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib62","doi-asserted-by":"crossref","first-page":"i581","DOI":"10.1136\/bmj.i581","article-title":"Incretin based drugs and the risk of pancreatic cancer: International multicentre cohort study","volume":"352","author":"Azoulay","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2026.07.010_bib63","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association between incretin-based drugs and the risk of acute pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib64","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101613","article-title":"Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis","volume":"51","author":"Nassar","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103116","article-title":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study","volume":"18","author":"Nassar","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.biopsych.2026.07.010_bib67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14740338.2024.2335215","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: What do we know and future vistas","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.biopsych.2026.07.010_bib68","article-title":"Alcohol use disorder and depressive disorders","volume":"40","author":"McHugh","year":"2019","journal-title":"Alcohol Res"},{"key":"10.1016\/j.biopsych.2026.07.010_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.biopsych.2026.07.010_bib70","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1626103","article-title":"Association of tirzepatide and the risk of suicide in a real-world cohort","volume":"16","author":"Yu","year":"2025","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib72","first-page":"1","article-title":"GLP-1 receptor agonists and risk of suicide or suicide attempts\u2014A nationwide cohort and self-controlled case series study","author":"Stanislaus","year":"2026","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib73","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: Post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.07.010_bib75","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/dc25-1238","article-title":"Association between GLP-1 receptor agonists and ischemic optic neuropathy: A meta-analysis","volume":"49","author":"Nogueira","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.07.010_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like Peptide-1 receptor analogues in type 2 diabetes: Their use and differential features","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.biopsych.2026.07.010_bib78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: A randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib80","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.07.010_bib81","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopsych.2026.07.010_bib82","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: Metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib83","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: The HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: A randomized clinical trial","volume":"83","author":"Sass","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss\u2013induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2026.07.010_bib86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.07.010_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-17927-w","article-title":"A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity","volume":"15","author":"Quddos","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2026.07.010_bib88","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib89","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1038\/s41380-025-03199-3","article-title":"Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: A multi-ancestry drug-target Mendelian randomization study","volume":"30","author":"Reitz","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: Neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes Rev"},{"key":"10.1016\/j.biopsych.2026.07.010_bib91","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4239\/wjd.v7.i20.572","article-title":"Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity","volume":"7","author":"Anandhakrishnan","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.biopsych.2026.07.010_bib92","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","article-title":"The neural basis of drug craving: An incentive-sensitization theory of addiction","volume":"18","author":"Robinson","year":"1993","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.biopsych.2026.07.010_bib93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.07.010_bib94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.07.010_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.07.010_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, Accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.07.010_bib97","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.010_bib98","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1530-0277.1996.tb05936.x","article-title":"Decreases in dopamine receptors but not in dopamine transporters in alcoholics","volume":"20","author":"Volkow","year":"1996","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2026.07.010_bib99","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1073\/pnas.1506012113","article-title":"Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence","volume":"113","author":"Hirth","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.07.010_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131017","article-title":"Reduced dopamine transporter availability and neurocognitive deficits in male patients with alcohol dependence","volume":"10","author":"Yen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.07.010_bib101","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrn3939","article-title":"The dopamine theory of addiction: 40 years of highs and lows","volume":"16","author":"Nutt","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.010_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochem Int"},{"key":"10.1016\/j.biopsych.2026.07.010_bib103","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.010_bib104","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1523\/JNEUROSCI.3371-07.2007","article-title":"Profound decreases in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement","volume":"27","author":"Volkow","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.010_bib105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib106","doi-asserted-by":"crossref","first-page":"15037","DOI":"10.1073\/pnas.1010654108","article-title":"Addiction: Beyond dopamine reward circuitry","volume":"108","author":"Volkow","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.07.010_bib107","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopsych.2026.07.010_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.15","article-title":"The link between inflammation, bugs, the intestine and the brain in alcohol dependence","volume":"7","author":"Leclercq","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.010_bib109","article-title":"The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.biopsych.2026.07.010_bib110","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/acer.70110","article-title":"Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial","volume":"49","author":"Hviid","year":"2025","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"10.1016\/j.biopsych.2026.07.010_bib111","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2008.02484.x","article-title":"Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes","volume":"25","author":"Courr\u00e8ges","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.biopsych.2026.07.010_bib112","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1092852920002217","article-title":"Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia","volume":"27","author":"M\u00f8ller","year":"2022","journal-title":"CNS Spectr"},{"key":"10.1016\/j.biopsych.2026.07.010_bib113","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pharep.2015.10.008","article-title":"Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes\/macrophages in a protein kinase A and B\/Akt manner","volume":"68","author":"Bu\u0142dak","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.biopsych.2026.07.010_bib114","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.07.010_bib115","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/acer.15118","article-title":"Medications for treating alcohol use disorder: A narrative review","volume":"47","author":"Kranzler","year":"2023","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"10.1016\/j.biopsych.2026.07.010_bib116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/TCRM.S23184","article-title":"Acamprosate for treatment of alcohol dependence: Mechanisms, efficacy, and clinical utility","volume":"8","author":"Witkiewitz","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.biopsych.2026.07.010_bib117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/add.15572","article-title":"Effect of extended-release naltrexone on alcohol consumption: A systematic review and meta-analysis","volume":"117","author":"Murphy","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.07.010_bib118","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/acer.12669","article-title":"Heterogeneity of alcohol use disorder: Understanding mechanisms to advance personalized treatment","volume":"39","author":"Litten","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2026.07.010_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:35:51Z","timestamp":1789587351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326014022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0006322326014022"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.07.010","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}